Caribou Biosciences – Another Gene Editing Stock

We’ll often see people leave comments on our articles like “I’m up +420% on stock X.” Without a timeframe and a benchmark, it’s impossible to know if that’s good or bad, but most people don’t recognize that paper returns mean nothing unless you sell and take profits. Plenty of investors watch their stocks rack up massive gains, only to then hold them until they fall below their cost basis. Human psychology makes it very difficult for people to figure out the best time to sell a stock. It’s a tough decision to make even with emotion removed, which is why you need to enter any given thesis with a great deal of conviction.

This past week, Intellia Therapeutics (NTLA) announced some positive news from their clinical trial in the form of a paper titled CRISPR-Cas9 In Vivo Gene-Editing for Transthyretin Amyloidosis. Long story short, they tested their gene-editing therapy on six patients and it worked really well – so far. As a result, gene-editing stocks soared across the board. When our position in Intellia crested a +1,250% return, we trimmed it a bit. That’s because the next news from Intellia could be that their therapy harms patients, and the stock could plummet as quickly as it soared. BioPharma Dive talks about